Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pembrolizumab study in advanced gynaecological clear cell cancer
2017-004168-36Phase 2Unknown
- Sponsor
- University College London
- Start
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in clear cell adenocarcinoma (CCA), clear cell ovarian cancer, clear cell endometrial carcinoma (CCEC) and 3 more, sponsored by University College London. Primary endpoint: Progression-free survival rate at 12 weeks. Status: unknown.
02
Drugs
03
Conditions
clear cell adenocarcinoma (CCA)clear cell ovarian cancerclear cell endometrial carcinoma (CCEC)Vaginal clear cell adenocarcinoma (CCA)Vulval carcinoma
Beyond the preview
Go deeper on 2017-004168-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004168-36.